Morphologic analysis of BMP-9 gene therapy-induced osteogenesis

P. Varady, Zhong Li Jin Zhong Li, M. Cunningham, E. J. Beres, S. Das, J. Engh, T. D. Alden, D. D. Pittman, K. M. Kerns, David F Kallmes, G. A. Helm

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

The present study was performed to determine the histological, ultrastructural, and radiographic changes that occur over time at intramuscular BMP-9 gene therapy treatment sites. Several members of the bone morphogenetic protein (BMP) family have the potential to induce osteochondrogenesis when the protein is delivered to rodents, canines, rabbits, and nonhuman primates. Previous studies have also demonstrated that BMP gene therapy utilizing adenoviral vectors can also stimulate orthotopic and heterotopic bone formation in rodents and rabbits. Athymic nude and Sprague-Dawley rats were injected with Ad-BMP-9 or Ad-β-Gal (3.75 × 109 particles) in their thigh musculature and light microscopic, electron microscopic, and computerized tomography analysis was performed 3, 6, 9, 12, 15, 18, 21, and 100 days later. To assess early mesenchymal cell proliferation, a bromodeoxyuridine (BrdU) immunohistochemical analysis was also performed 48, 60, and 72 hr postinjection in athymic nude rats. All animals demonstrated extensive endochondral bone formation at the Ad-BMP-9 treatment sites within 3 weeks. The Sprague-Dawley rats also exhibited a massive, acute inflammatory infiltrate during the first week. Proliferating mesenchymal stem cells were clearly evident as early as 2 days after treatment, which differentiated into small or hypertrophied chondrocytes during the next week. During the third week, the cartilaginous matrix mineralized and formed woven bone, which converted to lamellar bone by 3 months. No evidence of bone formation was demonstrated at the Ad-β-Gal injection sites in the athymic nude or Sprague-Dawley rats. In addition, no cellular proliferation was seen at the Ad-β-Gal treatment sites in the athymic nude animals as assessed by light microscopy and BrdU immunohistochemistry. The extensive bone formation induced by Ad-BMP-9 suggests that BMP gene therapy may have potential utility in the treatment of degenerative, rheumatic, or traumatic bone pathology.

Original languageEnglish (US)
Pages (from-to)697-710
Number of pages14
JournalHuman Gene Therapy
Volume12
Issue number6
DOIs
StatePublished - Apr 9 2001
Externally publishedYes

Fingerprint

Growth Differentiation Factor 2
Osteogenesis
Genetic Therapy
Bone Morphogenetic Proteins
Nude Rats
Sprague Dawley Rats
Bromodeoxyuridine
Bone and Bones
Rodentia
Cell Proliferation
Rabbits
Therapeutics
Light
Chondrocytes
Thigh
Mesenchymal Stromal Cells
Primates
Canidae
Microscopy
Immunohistochemistry

ASJC Scopus subject areas

  • Genetics

Cite this

Varady, P., Jin Zhong Li, Z. L., Cunningham, M., Beres, E. J., Das, S., Engh, J., ... Helm, G. A. (2001). Morphologic analysis of BMP-9 gene therapy-induced osteogenesis. Human Gene Therapy, 12(6), 697-710. https://doi.org/10.1089/104303401300057423

Morphologic analysis of BMP-9 gene therapy-induced osteogenesis. / Varady, P.; Jin Zhong Li, Zhong Li; Cunningham, M.; Beres, E. J.; Das, S.; Engh, J.; Alden, T. D.; Pittman, D. D.; Kerns, K. M.; Kallmes, David F; Helm, G. A.

In: Human Gene Therapy, Vol. 12, No. 6, 09.04.2001, p. 697-710.

Research output: Contribution to journalArticle

Varady, P, Jin Zhong Li, ZL, Cunningham, M, Beres, EJ, Das, S, Engh, J, Alden, TD, Pittman, DD, Kerns, KM, Kallmes, DF & Helm, GA 2001, 'Morphologic analysis of BMP-9 gene therapy-induced osteogenesis', Human Gene Therapy, vol. 12, no. 6, pp. 697-710. https://doi.org/10.1089/104303401300057423
Varady P, Jin Zhong Li ZL, Cunningham M, Beres EJ, Das S, Engh J et al. Morphologic analysis of BMP-9 gene therapy-induced osteogenesis. Human Gene Therapy. 2001 Apr 9;12(6):697-710. https://doi.org/10.1089/104303401300057423
Varady, P. ; Jin Zhong Li, Zhong Li ; Cunningham, M. ; Beres, E. J. ; Das, S. ; Engh, J. ; Alden, T. D. ; Pittman, D. D. ; Kerns, K. M. ; Kallmes, David F ; Helm, G. A. / Morphologic analysis of BMP-9 gene therapy-induced osteogenesis. In: Human Gene Therapy. 2001 ; Vol. 12, No. 6. pp. 697-710.
@article{d1c27c2e8bc743cd9b305a579204056a,
title = "Morphologic analysis of BMP-9 gene therapy-induced osteogenesis",
abstract = "The present study was performed to determine the histological, ultrastructural, and radiographic changes that occur over time at intramuscular BMP-9 gene therapy treatment sites. Several members of the bone morphogenetic protein (BMP) family have the potential to induce osteochondrogenesis when the protein is delivered to rodents, canines, rabbits, and nonhuman primates. Previous studies have also demonstrated that BMP gene therapy utilizing adenoviral vectors can also stimulate orthotopic and heterotopic bone formation in rodents and rabbits. Athymic nude and Sprague-Dawley rats were injected with Ad-BMP-9 or Ad-β-Gal (3.75 × 109 particles) in their thigh musculature and light microscopic, electron microscopic, and computerized tomography analysis was performed 3, 6, 9, 12, 15, 18, 21, and 100 days later. To assess early mesenchymal cell proliferation, a bromodeoxyuridine (BrdU) immunohistochemical analysis was also performed 48, 60, and 72 hr postinjection in athymic nude rats. All animals demonstrated extensive endochondral bone formation at the Ad-BMP-9 treatment sites within 3 weeks. The Sprague-Dawley rats also exhibited a massive, acute inflammatory infiltrate during the first week. Proliferating mesenchymal stem cells were clearly evident as early as 2 days after treatment, which differentiated into small or hypertrophied chondrocytes during the next week. During the third week, the cartilaginous matrix mineralized and formed woven bone, which converted to lamellar bone by 3 months. No evidence of bone formation was demonstrated at the Ad-β-Gal injection sites in the athymic nude or Sprague-Dawley rats. In addition, no cellular proliferation was seen at the Ad-β-Gal treatment sites in the athymic nude animals as assessed by light microscopy and BrdU immunohistochemistry. The extensive bone formation induced by Ad-BMP-9 suggests that BMP gene therapy may have potential utility in the treatment of degenerative, rheumatic, or traumatic bone pathology.",
author = "P. Varady and {Jin Zhong Li}, {Zhong Li} and M. Cunningham and Beres, {E. J.} and S. Das and J. Engh and Alden, {T. D.} and Pittman, {D. D.} and Kerns, {K. M.} and Kallmes, {David F} and Helm, {G. A.}",
year = "2001",
month = "4",
day = "9",
doi = "10.1089/104303401300057423",
language = "English (US)",
volume = "12",
pages = "697--710",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Morphologic analysis of BMP-9 gene therapy-induced osteogenesis

AU - Varady, P.

AU - Jin Zhong Li, Zhong Li

AU - Cunningham, M.

AU - Beres, E. J.

AU - Das, S.

AU - Engh, J.

AU - Alden, T. D.

AU - Pittman, D. D.

AU - Kerns, K. M.

AU - Kallmes, David F

AU - Helm, G. A.

PY - 2001/4/9

Y1 - 2001/4/9

N2 - The present study was performed to determine the histological, ultrastructural, and radiographic changes that occur over time at intramuscular BMP-9 gene therapy treatment sites. Several members of the bone morphogenetic protein (BMP) family have the potential to induce osteochondrogenesis when the protein is delivered to rodents, canines, rabbits, and nonhuman primates. Previous studies have also demonstrated that BMP gene therapy utilizing adenoviral vectors can also stimulate orthotopic and heterotopic bone formation in rodents and rabbits. Athymic nude and Sprague-Dawley rats were injected with Ad-BMP-9 or Ad-β-Gal (3.75 × 109 particles) in their thigh musculature and light microscopic, electron microscopic, and computerized tomography analysis was performed 3, 6, 9, 12, 15, 18, 21, and 100 days later. To assess early mesenchymal cell proliferation, a bromodeoxyuridine (BrdU) immunohistochemical analysis was also performed 48, 60, and 72 hr postinjection in athymic nude rats. All animals demonstrated extensive endochondral bone formation at the Ad-BMP-9 treatment sites within 3 weeks. The Sprague-Dawley rats also exhibited a massive, acute inflammatory infiltrate during the first week. Proliferating mesenchymal stem cells were clearly evident as early as 2 days after treatment, which differentiated into small or hypertrophied chondrocytes during the next week. During the third week, the cartilaginous matrix mineralized and formed woven bone, which converted to lamellar bone by 3 months. No evidence of bone formation was demonstrated at the Ad-β-Gal injection sites in the athymic nude or Sprague-Dawley rats. In addition, no cellular proliferation was seen at the Ad-β-Gal treatment sites in the athymic nude animals as assessed by light microscopy and BrdU immunohistochemistry. The extensive bone formation induced by Ad-BMP-9 suggests that BMP gene therapy may have potential utility in the treatment of degenerative, rheumatic, or traumatic bone pathology.

AB - The present study was performed to determine the histological, ultrastructural, and radiographic changes that occur over time at intramuscular BMP-9 gene therapy treatment sites. Several members of the bone morphogenetic protein (BMP) family have the potential to induce osteochondrogenesis when the protein is delivered to rodents, canines, rabbits, and nonhuman primates. Previous studies have also demonstrated that BMP gene therapy utilizing adenoviral vectors can also stimulate orthotopic and heterotopic bone formation in rodents and rabbits. Athymic nude and Sprague-Dawley rats were injected with Ad-BMP-9 or Ad-β-Gal (3.75 × 109 particles) in their thigh musculature and light microscopic, electron microscopic, and computerized tomography analysis was performed 3, 6, 9, 12, 15, 18, 21, and 100 days later. To assess early mesenchymal cell proliferation, a bromodeoxyuridine (BrdU) immunohistochemical analysis was also performed 48, 60, and 72 hr postinjection in athymic nude rats. All animals demonstrated extensive endochondral bone formation at the Ad-BMP-9 treatment sites within 3 weeks. The Sprague-Dawley rats also exhibited a massive, acute inflammatory infiltrate during the first week. Proliferating mesenchymal stem cells were clearly evident as early as 2 days after treatment, which differentiated into small or hypertrophied chondrocytes during the next week. During the third week, the cartilaginous matrix mineralized and formed woven bone, which converted to lamellar bone by 3 months. No evidence of bone formation was demonstrated at the Ad-β-Gal injection sites in the athymic nude or Sprague-Dawley rats. In addition, no cellular proliferation was seen at the Ad-β-Gal treatment sites in the athymic nude animals as assessed by light microscopy and BrdU immunohistochemistry. The extensive bone formation induced by Ad-BMP-9 suggests that BMP gene therapy may have potential utility in the treatment of degenerative, rheumatic, or traumatic bone pathology.

UR - http://www.scopus.com/inward/record.url?scp=0035831609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035831609&partnerID=8YFLogxK

U2 - 10.1089/104303401300057423

DO - 10.1089/104303401300057423

M3 - Article

C2 - 11426468

AN - SCOPUS:0035831609

VL - 12

SP - 697

EP - 710

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 6

ER -